Equities research analysts at William Blair lowered their Q2 2026 earnings per share estimates for Zumiez in a report ...

Investment analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for U.S. Physical Therapy in a ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Investing.com -- William Blair upgraded Palantir Technologies (NASDAQ: PLTR) to Market Perform following a 33% selloff from ...

William Blair upgraded Zealand Pharma (ZLDPF) to Outperform from Market Perform without a price target The firm sees the recent share pullback ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.